You just read:

Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

News provided by

Valeant Pharmaceuticals International, Inc.

Jan 29, 2015, 21:00 ET